Literature DB >> 20865330

Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma.

Haeyoun Kang1, Byung Soh Min, Kang Young Lee, Nam Kyu Kim, Soo Nyung Kim, Junjeong Choi, Hoguen Kim.   

Abstract

BACKGROUND: With the recent development of molecular markers, it has become possible to characterize colorectal carcinomas beyond clinical and histologic aspects. When considered together with tumor stage, molecular markers will allow us further insight into individual tumor biologies and prognoses.
PURPOSE: To investigate the expression and prognostic implications of the molecular markers, p53, bcl-2, Rb, hMLH1, hMSH2, β-catenin, E-cadherin, and MUC-2.
METHODS: We analyzed the clinical, histologic, and molecular factors for 229 patients with colorectal carcinoma of stage II and III and compared their prognoses. We used tissue microarrays to analyze the expressions of molecular markers and to assess their correlations with prognosis. Semiquantitative expressions of molecular markers and clinicopathologic parameters were analyzed with respect to prognosis.
RESULTS: Among the clinicopathologic parameters, left-sided location, age older than 70 years, higher preoperative serum carcinoembryonic antigen (CEA) level (≤ 5 ng/mL), irregular growth pattern, and perineural invasion were significantly related to poor prognosis in stage II and III patients. For molecular factors, loss of expression of E-cadherin and MUC-2 showed significant correlation with poor overall survival in both cancer stages. Multivariate analysis showed that higher TNM stage, higher preoperative serum CEA level (≤ 5 ng/mL), perineural tumor cell invasion, and loss of E-cadherin and MUC-2 expressions were independently correlated with poor overall survival.
CONCLUSIONS: Our results indicated that of the analyzed molecular markers, MUC-2 and E-cadherin might be useful in predicting prognosis and planning for adjuvant therapy in patients with stage II and III colorectal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865330     DOI: 10.1245/s10434-010-1338-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  34 in total

1.  Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.

Authors:  Malik Quasir Mahmood; Chris Ward; Hans Konrad Muller; Sukhwinder Singh Sohal; Eugene Haydn Walters
Journal:  Med Oncol       Date:  2017-02-14       Impact factor: 3.064

Review 2.  Prognostic value of perineural invasion in colorectal cancer: a meta-analysis.

Authors:  Yuchong Yang; Xuanzhang Huang; Jingxu Sun; Peng Gao; Yongxi Song; Xiaowan Chen; Junhua Zhao; Zhenning Wang
Journal:  J Gastrointest Surg       Date:  2015-02-07       Impact factor: 3.452

3.  Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics.

Authors:  Haipeng Wang; Shengjian Jin; Huiling Lu; Sisi Mi; Wenhua Shao; Xiaoxv Zuo; Huangyi Yin; Sien Zeng; Fumio Shimamoto; Guangying Qi
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

4.  Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer.

Authors:  Teppei Morikawa; Aya Kuchiba; Zhi Rong Qian; Mari Mino-Kenudson; Jason L Hornick; Mai Yamauchi; Yu Imamura; Xiaoyun Liao; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Ann Surg Oncol       Date:  2011-12-22       Impact factor: 5.344

Review 5.  Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer.

Authors:  Lorena Losi; Tommaso Zanocco-Marani; Alexis Grande
Journal:  Histol Histopathol       Date:  2020-06-22       Impact factor: 2.303

6.  Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer.

Authors:  Shiv Ram Krishn; Sukhwinder Kaur; Lynette M Smith; Sonny L Johansson; Maneesh Jain; Asish Patel; Shailendra K Gautam; Michael A Hollingsworth; Ulla Mandel; Henrik Clausen; Wing-Cheong Lo; Wai-Tong Louis Fan; Upender Manne; Surinder K Batra
Journal:  Cancer Lett       Date:  2016-02-16       Impact factor: 8.679

7.  Clinicopathological Significance of Mucin 2 Immuno-histochemical Expression in Colorectal Cancer: A Meta-Analysis.

Authors:  Li Li; Pei-Lin Huang; Xiao-Jin Yu; Xiao-Dong Bu
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

8.  Clinical significance of mucinous components in rectal cancer after preoperative chemoradiotherapy.

Authors:  Kensuke Kaneko; Kazushige Kawai; Shinsuke Kazama; Koji Murono; Kazuhito Sasaki; Koji Yasuda; Kensuke Ohtani; Takeshi Nishikawa; Toshiaki Tanaka; Tomomichi Kiyomatsu; Keisuke Hata; Hiroaki Nozawa; Soichiro Ishihara; Teppei Morikawa; Masashi Fukayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2016-09-22       Impact factor: 2.549

Review 9.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Authors:  Yoshinori Inagaki; Jianjun Gao; Peipei Song; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

10.  Transmembrane mucin MUC1 overexpression and its association with CD10⁺ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer.

Authors:  Do Trong Khanh; Eiji Mekata; Ken-ichi Mukaisho; Hiroyuki Sugihara; Tomoharu Shimizu; Hisanori Shiomi; Satoshi Murata; Shigeyuki Naka; Hiroshi Yamamoto; Yoshihiro Endo; Tohru Tani
Journal:  Cancer Sci       Date:  2013-05-21       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.